FNT
REGN icon

First National Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

First National Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-306
Closed -$218K – 404
2024
Q4 		$218K Hold
306
– – 0.01% 372
2024
Q3 		$322K Buy
306
+100
+49% +$111K 0.01% 326
2024
Q2 		$217K Buy
+206
New +$200K 0.01% 363

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First National Trust's REGN Position: Q1 2025 in Review

First National Trust sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 306 shares — an estimated $218K sold.

First National Trust first reported a position in REGN in Q2 2024 and held it in 3 quarters. The position peaked at $322K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • First National Trust reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • First National Trust sold 306 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $218K.
  • First National Trust first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • First National Trust's Regeneron Pharmaceuticals position peaked at $322K in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on First National Trust's 13F filing for Q1 2025, filed 8 May 2025.